SEC. 5. NOTIFICATION OF AGREEMENTS. 
Section 1112 of the Medicare Prescription Drug, Im-
provement, and Modernization Act of 2003 (21 U.S.C. 
355 note) is amended by adding at the end the following: 
‘‘(4) RULE OF CONSTRUCTION.— 
‘‘(A) An agreement that is required in sub-
section (a) or (b) shall include agreements re-
solving any outstanding disputes, including 
agreements resolving or settling a Patent Trial 
and Appeal Board proceeding. 
‘‘(B) For purposes of subparagraph (A), 
the term ‘Patent Trial and Appeal Board pro-
ceeding’ means a proceeding conducted by the 
United States Patent and Trademark Office 
Patent Trial and Appeal Board, including but 
not limited to inter parties review, post-grant 
review, the transitional program for covered 
business method patents, and derivation pro-
ceedings.’’. 
SEC. 6. FORFEITURE OF 180-DAY EXCLUSIVITY PERIOD. 
Section 505(j)(5)(D)(i)(V) of the Federal Food, 
Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(D)(i)(V)) 
is amended by inserting ‘‘section 27 of the Federal Trade 
Commission Act or’’ after ‘‘that the agreement has vio-
lated’’. 
VerDate Sep 11 2014 
00:28 Apr 30, 2019
Jkt 089200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6201
E:\BILLS\H2375.IH
H2375
pamtmann on DSKBFK8HB2PROD with BILLS
SEC. 7. COMMISSION LITIGATION AUTHORITY. 
Section 16(a)(2) of the Federal Trade Commission 
Act (15 U.S.C. 56(a)(2)) is amended— 
(1) in subparagraph (D), by striking ‘‘or’’ after 
the semicolon; 
(2) in subparagraph (E), by inserting ‘‘or’’ 
after the semicolon; and 
(3) inserting after subparagraph (E) the fol-
lowing: 
‘‘(F) under section 27;’’. 
SEC. 8. REPORT ON ADDITIONAL EXCLUSION. 
Within 1 year of enactment, the Federal Trade Com-
mission shall provide a recommendation, and the Commis-
sion’s basis for it, to the Committee on the Judiciary of 
the House of Representatives and the Committee on the 
Judiciary of the Senate regarding a potential amendment 
to include in section 27(c) of the Federal Trade Commis-
sion Act, an additional exclusion for consideration granted 
by an NDA holder or biological product license holder to 
the ANDA filer or biosimilar biological product application 
filer, respectively, as part of the resolution or settlement, 
a release, waiver, or limitation of a claim for damages or 
other monetary relief. 
SEC. 9. STATUTE OF LIMITATIONS. 
The Federal Trade Commission shall commence any 
enforcement proceeding described in section 27 of the 
VerDate Sep 11 2014 
01:50 Apr 30, 2019
Jkt 089200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6201
E:\BILLS\H2375.IH
H2375
pamtmann on DSKBFK8HB2PROD with BILLS
Federal Trade Commission Act, as added by section 3, ex-
cept for an action described in section 27(f)(2) of the Fed-
eral Trade Commission Act, not later than 6 years after 
the date on which the parties to the agreement file the 
certification under section 1112(d) of the Medicare Pre-
scription Drug, Improvement, and Modernization Act of 
2003 (21 U.S.C. 355 note). 
SEC. 10. SEVERABILITY. 
If any provision of this Act, an amendment made by 
this Act, or the application of such provision or amend-
ment to any person or circumstance is held to be unconsti-
tutional, the remainder of this Act, the amendments made 
by this Act, and the application of the provisions of such 
Act or amendments to any person or circumstance shall 
not be affected. 
Æ 
VerDate Sep 11 2014 
00:28 Apr 30, 2019
Jkt 089200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6301
E:\BILLS\H2375.IH
H2375
pamtmann on DSKBFK8HB2PROD with BILLS